Stopping arthritis medication in children with juvenile idiopathic arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study looks at when it may be safe to stop or reduce arthritis medications in children whose juvenile idiopathic arthritis has been inactive for at least 6 months. The goal is to find the best time to stop treatment to avoid side effects while preventing flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has juvenile idiopathic arthritis (JIA) as diagnosed by a doctor.
- The arthritis has been inactive (no symptoms) for at least 6 months while still taking medication.
- Your child has been treated with disease-modifying anti-rheumatic drugs (DMARDs) as prescribed.
- You and your child are willing to follow the study procedures and give written consent.
- If your child is a female of childbearing age, she must have a negative pregnancy test and not plan to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if removing certain foods can improve arthritis symptoms in children aged 6 to 17. It may be an option if current medicines are not working well or if you want to explore dietary changes.
This study looks at how juvenile idiopathic arthritis (JIA), a type of childhood arthritis, affects joints like the hands, hips, and knees after a person moves from pediatric to adult care. It helps understand if joint damage worsens over time, which could guide future treatment.
This study follows people with rheumatoid arthritis (RA) who have achieved remission—meaning their disease is well-controlled—to see how safely doctors can reduce or stop their medications over time. You would be monitored regularly to ensure your RA stays in remission.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This Phase 3 study tests whether children with early juvenile idiopathic arthritis do better by starting with one treatment approach and adjusting (stepping up or stepping down) based on how their arthritis responds. It may help find the safest, most effective long-term plan for controlling symptoms with fewer side effects.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Hear when a new Juvenile Idiopathic Arthritis (JIA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.